Susana Otero-Romero

Jun 9, 2023 | journals.sagepub.com | Susana Otero-Romero |Christine Lebrun-Frenay |Saúl Reyes |Maria amato

AbstractBackground:With the new highly active drugs available for people with multiple sclerosis (pwMS), vaccination becomes an essential part of the risk management strategyObjective:To develop a European evidence-based consensus for the vaccination strategy of pwMS who are candidates for disease-modifying therapies (DMTs). Methods:This work was conducted by a multidisciplinary working group using formal consensus methodology.

Jun 9, 2023 | journals.sagepub.com | Susana Otero-Romero |Christine Lebrun-Frenay |Saúl Reyes |Maria amato

IntroductionOver the last years, there has been a relevant change in the long-term prognosis of people with multiple sclerosis (pwMS), mainly due to the regulatory approval of a range of highly active immunotherapies with mechanisms of action that include alteration of lymphocyte trafficking, lymphocyte depletion and disruption of lymphocyte replication.

Jun 9, 2023 | journals.sagepub.com | Susana Otero-Romero |Christine Lebrun-Frenay |Saúl Reyes |Maria amato

AbstractBackground:With the new highly active drugs available for people with multiple sclerosis (pwMS), vaccination becomes an essential part of the risk management strategyObjective:To develop a European evidence-based consensus for the vaccination strategy of pwMS who are candidates for disease-modifying therapies (DMTs). Methods:This work was conducted by a multidisciplinary working group using formal consensus methodology.